Table 3.
Characteristics of CCP-treated COVID-19 patients, dead and alive.
| Parameters | Alive n = 18 (85.7%) |
Dead n = 3 (14.3%) |
p |
|---|---|---|---|
| Median age, years (IQR) |
60.5 (50.0–72.0) |
78 (77.5–79.5) |
0.03 |
| Sex (males/females), number |
15/3 | 3/0 | - |
| Median BMI (kg/m2) (IQR) |
27.0 (24.0–32.0) |
28.0 (27.0–31.5) |
NS |
| Comorbidities, n (%) <3 ≥3 |
6 (33.3) 12 (66.7) |
0 (0) 3 (100) |
- |
| PaO2/FiO2, median (IQR) |
138.5 (115.5–154.3) |
86.0 (79.0–87.0) |
0.03 |
| Days between symptom onset and CCP therapy, median (IQR) | 9 (6.0–10.8) | 18 (12.0–18.5) | 0.02 |
| CCP units transfused, mean (±SD) |
1.8 (±0.8) |
1.7 (±0.6) |
NS |
| CCP neutralizing titer, mean (±SD) |
360.0 (±203.2) |
384.0 (±242.6) |
NS |
Abbreviations: NS, not significant; CCP, COVID-19 convalescent plasma; BMI, body mass index; SD, standard deviation.